文献速递肿瘤 PET/CT

18F-rhPSMA-7 PET对高危前列腺癌原发N分期的组织学验证诊断效能

Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer.
PubMed 文献 · J Nucl Med · 2019-12-13

该回顾性研究纳入58例高危前列腺癌患者,均行18F-rhPSMA-7 PET/CT或PET/MRI后接受根治性前列腺切除及扩大盆腔淋巴结清扫,以组织病理为金标准比较PET与形态学成像的N分期效能。PET在患者水平和模板水平均显著优于形态学成像,结论认为18F-rhPSMA-7 PET对高危原发前列腺癌N分期优于形态学成像,效能与已发表的68Ga-PSMA-11数据相似。

要点

  • 18F-rhPSMA-7 PET对高危前列腺癌N分期优于CT或MRI形态学成像
  • 患者水平PET灵敏度72.2%、特异度92.5%、准确率86.2%
  • 模板水平PET灵敏度53.8%、特异度96.9%、准确率90.9%

核心结论

  • 18F-rhPSMA-7 PET对高危原发前列腺癌的N分期优于形态学成像。
  • 18F-rhPSMA-7的效能与已发表的68Ga-PSMA-11数据相似。

研究设计与样本

  • 回顾性分析58例按D'Amico标准定义的高危前列腺癌患者。
  • 患者于2017年7月至2018年6月在本机构行18F-rhPSMA-7 PET/CT或PET/MRI分期。
  • 所有患者随后接受根治性前列腺切除和扩大盆腔淋巴结清扫。
  • 由经验丰富的阅片者独立对PET和形态学数据集采用基于模板的5分法分析。
  • 患者水平和基于模板的结果均与组织病理学发现比较。

主要发现

  • 18例患者(31.0%)存在淋巴结转移,转移位于375个模板中的52个(13.9%)。
  • 患者水平ROC分析AUC:PET 0.858 vs 形态学成像 0.649(P=0.012)。
  • 模板水平ROC分析AUC:PET 0.765 vs 形态学成像 0.589(P<0.001)。
  • 患者水平PET灵敏度72.2%、特异度92.5%、准确率86.2%;形态学成像分别为50.0%、72.5%、65.5%。
  • 模板水平PET灵敏度53.8%、特异度96.9%、准确率90.9%;形态学成像分别为9.6%、95.0%、83.2%。

关键数值与推荐

  • 患者扫描前前列腺特异性抗原中位值12.2 ng/mL(范围1.2-81.6 ng/mL)。
  • 18F-rhPSMA-7中位注射活度327 MBq(范围132-410 MBq),中位摄取时间79.5 min(范围60-153 min)。

临床怎么用

  • 对高危前列腺癌患者,18F-rhPSMA-7 PET可用于原发N分期,其诊断效能优于CT或MRI形态学成像。
  • 判读时可结合患者水平和基于模板的5分法分析,以提高淋巴结转移检出。

局限性

  • 本文为回顾性分析,样本量58例,来自单机构。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-rhPSMA-7 (radiohybrid prostate-specific membrane antigen [PSMA]) is a novel ligand for PET imaging. Here, we present data from a retrospective analysis using PET/CT and PET/MRI examinations to investigate the efficacy of 18F-rhPSMA-7 PET for primary N-staging of patients with prostate cancer (PC) compared with morphologic imaging (CT or MRI) and validated by histopathology. Methods: Data from 58 patients with high-risk PC (according to the D'Amico criteria) who were staged with 18F-rhPSMA-7 PET/CT or PET/MRI at our institution between July 2017 and June 2018 were reviewed. The patients had a median prescan prostate-specific antigen value of 12.2 ng/mL (range, 1.2-81.6 ng/mL). The median injected activity of 18F-rhPSMA-7 was 327 MBq (range, 132-410 MBq), with a median uptake time of 79.5 min (range, 60-153 min). All patients underwent subsequent radical prostatectomy and extended pelvic lymph node dissection. The presence of lymph node metastases was determined by an experienced reader independently for both the PET and the morphologic datasets using a template-based analysis on a 5-point scale. Patient-level and template-based results were both compared with histopathologic findings. Results: Lymph node metastases were present in 18 patients (31.0%) and were located in 52 of 375 templates (13.9%). Receiver-operating-characteristic analyses showed 18F-rhPSMA-7 PET to perform significantly better than morphologic imaging on both patient-based and template-based analyses (areas under curve, 0.858 vs. 0.649 [P = 0.012] and 0.765 vs. 0.589 [P < 0.001], respectively). On patient-based analyses, the sensitivity, specificity, and accuracy of 18F-rhPSMA-7 PET were 72.2%, 92.5%, and 86.2%, respectively, and those of morphologic imaging were 50.0%, 72.5%, and 65.5%, respectively. On template-based analyses, the sensitivity, specificity, and accuracy of 18F-rhPSMA-7 PET were 53.8%, 96.9%, and 90.9%, respectively, and those of morphologic imaging were 9.6%, 95.0%, and 83.2%, respectively. Conclusion:18F-rhPSMA-7 PET is superior to morphologic imaging for N-staging of high-risk primary PC. The efficacy of 18F-rhPSMA-7 is similar to published data for 68Ga-PSMA-11.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kroenke M, Wurzer A, Schwamborn K, et al. Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. J Nucl Med. 2019. PMID: 31836681. doi:10.2967/jnumed.119.234906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。